Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin as lincomycin hydrochloride; spectinomycin as spectinomycin sulfate - oral powder, pre-mix - lincomycin as lincomycin hydrochloride antibiotic active 22.0 g/kg; spectinomycin as spectinomycin sulfate antibiotic active 22.0 g/kg - nutrition & metabolism - pigs | boar | gilt | piglet | sow | swine - bloody scours | enteritis associated with e.coli | mycoplasmal pneumonia | promote animal growth | salmonellosis | vibrionic dysentery | feed conversion | finishing | growth promotion | growth rate | liveweight gain | swine dysentery

United States - English - NLM (National Library of Medicine)

med-pharmex, inc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 0.4 g in 1 g

United States - English - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 50 g in 0.453 kg

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin lws is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin lws is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin lws is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin lws is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

United States - English - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincocin products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. the drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. systemic therapy with lincocin has been shown to be of benefit in many animals with pustular dermatitis. as with all antibiotics, in vitro sensitivity studies should be performed before lincocin is utilized as sole antibiotic therapy. lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. the drug may be administered in combination therapy with other antimicrobial agents when indicated. no serious hypersensitivity reactions have been reported and many animals have received lincocin repeatedly without developing evidence of hypersensitivity. lincocin has demonstrated e

United States - English - NLM (National Library of Medicine)

sparhawk laboratories, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - 300 mg/ml  sterile lincomycin injection caution:federal law restricts this drug to use by or on the order of a licenced veterinarian.  swine antibiotic indicated for the treatment of arthritis caused by susceptible ortanisims and for mycoplasma pneumonia. lincomycin injectable contains lincomycin hydrochloride, an antibiotic produced bysteptomyces lincolnensis var. lincolnensis , which is chemically distinct from all other clinically avaialbel antibiotics and is isolated as a white crystalline solid caution: federal law restricts this drug to use by or on the order of a licensed veterinarian. not for use in humans keep out of reach of children indications for swine lincomycin injectable is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci,erysipelothrix and  mycoplasma spp. as with all drugs, the use of lincomycin inje

United States - English - NLM (National Library of Medicine)

huvepharma, inc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f), spectinomycin hydrochloride (unii: hwt06h303z) (spectinomycin - unii:93aki1u6qf) -                                                             directions for use indications and usage: for use in chickens up to 7 days of age as an aid in the control of: airsacculitis caused by either mycoplasma synoviae  or mycoplasma gallisepticum  susceptible to lincomycin-spectinomycin. complicated chronic respiratory disease (air sac infection) caused by escherichia coli  and m. gallisepticum susceptible to lincomycin-spectinomycin. warning:    not for human use                      keep out of reach of children to report suspected adverse drug events, for technical assistance or to obtain a copy of the safety data sheet (sds), contact huvepharma, inc. at 1-877-994-4883 or www.huvepharma.us. for additional information about adverse drug experience reporting for animal drugs, contact fda at 1-888-fda-vets or http://www.fda.gov/reportanimalae.

United States - English - NLM (National Library of Medicine)

aspen veterinary resources - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f), spectinomycin hydrochloride (unii: hwt06h303z) (spectinomycin - unii:93aki1u6qf) - directions for use indications and usage: for use in chickens up to 7 days of age as an aid in the control of: airsacculitis caused by either mycoplasma synoviae or mycoplasma gallisepticum susceptible to lincomycin-spectinomycin. complicated chronic respiratory disease (air sac infection) caused by escherichia coli and m. gallisepticum susceptible to lincomycin-spectinomycin.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

v.m.d. sa-nv - lincomycin hydrochloride - eq. lincomycin 100 mg/ml - solution for injection - 100 mg/ml - lincomycin hydrochloride - lincomycin - pig